Tiziana announces positive qualitative six-month pet scan results with intranasal foralumab treating multiple sclerosis patients diagnosed with non-active secondary progressive ms (na-spms)

New york, oct. 13, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month positron emission tomography (pet) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-spms) treated with intranasal foralumab in its expanded access program (eap). activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, alzheimer's disease, and amyotrophic lateral sclerosis, or als.
TLSA Ratings Summary
TLSA Quant Ranking